What Happened
- The ongoing US-Iran war in West Asia threatens up to Rs 5,000 crore of India's pharmaceutical exports to the region due to surging freight costs and maritime route disruptions
- Freight charges for both exports and imports have doubled, with surcharges of $4,000–$8,000 per shipment, as key shipping routes through the Red Sea, Strait of Hormuz, and Gulf corridors face rerouting and delays
- Raw material costs for key pharmaceutical inputs have risen by approximately 30%, driven by container ship scarcity and freight surges — India imports significant volumes of Active Pharmaceutical Ingredients (APIs) from China via sea routes
- Countries like the UAE, Saudi Arabia, Oman, Kuwait, and Yemen — which rely on India for cost-effective medicines — face potential supply disruptions, particularly for temperature-sensitive drugs
- Indian pharmaceutical exports to the West Asia and North Africa (WANA) region grew from $1,320 million in FY 2020-21 to $1,750 million in FY 2024-25, making the region a significant and growing market
Static Topic Bridges
India's Pharmaceutical Industry — "Pharmacy of the World"
India is the world's third-largest pharmaceutical producer by volume and 14th by value, with over 3,000 companies, 10,500 manufacturing units, and more than 60,000 generic brands across 60 therapeutic areas. India supplies approximately 20% of the world's generic medicines by volume and is a leading supplier of affordable drugs to developing countries in Africa, Latin America, and Asia.
- Total pharmaceutical exports FY 2024-25: $30.47 billion (9.4% growth over previous year)
- Drug Formulations and Biologicals: $22,929 million (75% of total exports); Bulk Drugs/APIs: $4,870 million; Vaccines: $1,222 million
- Top export destinations: NAFTA region (37.6%, primarily US), Europe (18.9%), Africa (12.9%)
- India's share of global pharma market by value: 5.71%
- Key regulatory bodies: Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940; National Pharmaceutical Pricing Authority (NPPA) for price control
- India supplies 60% of global vaccine demand; Serum Institute of India is the world's largest vaccine manufacturer by doses
Connection to this news: The Rs 5,000 crore export risk highlights the vulnerability of India's pharma export model, which relies heavily on sea-based logistics through conflict-prone maritime chokepoints in the Gulf region.
API Dependency and Supply Chain Vulnerability
Active Pharmaceutical Ingredients (APIs) are the biologically active components in medicines that produce the intended therapeutic effect. India imports approximately 68% of its API requirements from China, creating a significant supply chain vulnerability. The Bulk Drug Parks policy (2020) and the Production Linked Incentive (PLI) Scheme for pharmaceuticals (2021) were launched to reduce this dependency.
- India imports ~68% of APIs and drug intermediates from China, including critical inputs like paracetamol, ibuprofen, and key antibiotics
- Key APIs with near-total Chinese dependence: Penicillin-G (~100%), Vitamin B12 (~100%), Azithromycin (~90%)
- PLI Scheme for Pharmaceuticals: Rs 15,000 crore outlay (2021–2028); covers 41 identified products across 3 categories
- Bulk Drug Parks Scheme: Rs 3,000 crore for 3 mega parks (Himachal Pradesh, Andhra Pradesh, Gujarat) to manufacture critical APIs domestically
- Katoch Committee (2015) first flagged India's dangerous API import dependence on China
- Jan Aushadhi Scheme: Government initiative to provide quality generic medicines at affordable prices through dedicated stores (10,000+ Jan Aushadhi Kendras)
Connection to this news: The West Asia conflict compounds India's existing API vulnerability — Chinese raw materials shipped via sea routes through the Strait of Hormuz face delays and cost escalation, while finished drug exports to Gulf nations face similar logistics disruptions.
Strait of Hormuz and Maritime Trade Routes — Chokepoint Risks
The Strait of Hormuz, located between Iran and Oman, is the world's most critical energy and trade chokepoint. Beyond oil, it is a major conduit for containerised cargo, including pharmaceutical shipments between India and Gulf nations. Any disruption to this route forces cargo rerouting via the Cape of Good Hope, adding 10–15 days and significantly increasing costs.
- Daily oil transit: ~20 million barrels/day (~25% of seaborne oil trade globally)
- Width at narrowest point: ~33 km; navigable shipping lanes: ~6 km total (3 km each direction)
- Alternative routes: Cape of Good Hope adds ~6,500 nautical miles and 10–15 days to transit
- 84% of crude transiting the Strait goes to Asian markets — China, India, Japan, South Korea account for 69% of flows
- India's dependence: ~60% of crude oil imports transit the Strait of Hormuz
- The Red Sea (Bab el-Mandeb Strait) is another critical chokepoint already disrupted since 2023 by Houthi attacks on shipping
Connection to this news: The pharma export threat is a direct consequence of maritime route insecurity — doubling of freight costs and container shortages reflect the cascading impact of conflict on the Strait of Hormuz and Red Sea shipping corridors that India's pharma trade depends on.
Key Facts & Data
- Pharma export risk: Rs 2,500–5,000 crore to the West Asia region
- India's total pharma exports FY 2024-25: $30.47 billion
- Freight surcharge increase: $4,000–$8,000 per shipment
- Raw material cost increase: ~30% for key pharmaceutical inputs
- API import dependence on China: ~68%
- PLI Scheme for Pharma: Rs 15,000 crore; Bulk Drug Parks: Rs 3,000 crore
- India supplies ~20% of world's generic drugs by volume; 60% of global vaccine demand
- Pharma exports to WANA region: $1,750 million in FY 2024-25 (up from $1,320 million in FY 2020-21)